Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17269703 | 0.76 | MAOA (0.47) | MAOAMAOBACHETSHRHPGD | |
| SCHEMBL21765014 | 0.76 | MAOA (0.39) | MAOAMAOBACHETSHRHPGD | |
| SCHEMBL2771852 | 0.75 | MAOA (0.50) | MAOAMAOBACHETSHRHPGD | |
| SCHEMBL21440264 | 0.75 | ERCC5 (0.41) | MAOAMAOBTSHRHPGDERCC5 | |
| SCHEMBL21791009 | 0.74 | ALDH1A1 (0.40) | ACHETSHRHPGDKMT2A | |
| SCHEMBL24080244 | 0.74 | MEN1 (0.42) | TSHRHPGDHTTNPC1SMN1; SMN2 | |
| SCHEMBL22343688 | 0.74 | MAOA (0.42) | MAOAMAOBACHETSHRHPGD | |
| SCHEMBL18790247 | 0.74 | MAOA (0.39) | MAOAMAOBACHETSHRHPGD | |
| SCHEMBL272167 | 0.73 | MAOA (0.48) | MAOAMAOBACHETSHRHPGD | |
| SCHEMBL318284 | 0.73 | MAOA (0.48) | MAOAMAOBACHETSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365606-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| EP-3287441-B1 | ACYLATED 4-AMINOPIPERIDINES AS INHIBITORS OF SERINE PALMITOYLTRANSFERASE | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| WO-2018059263-A1 | BISMUTH (III) COMPOUNDS AND METHODS THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365606-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OXER1, OPRD1, OXSR1 | MAOA 857/4885MAOB 759/4885ACHE 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.